In addition, increased EZH2, which is a common hallmark of NMIBC at high risk of recurrence and tumor progression in recurrences [117], also caused a decrease of miR-200 family expression, and the knock down of EZH2 or its inhibition, using DZNep (3-Deazaneplanocin A), resulted in an increased expression of the miR-200 family in BC cell lines [108]. The gene discussed is EZH2; the disease is breast cancer.